Although the association with aggressive clinical characteristics of HCC indicated KPNA2 as a potential therapeutic target, targeting of the factor would probably be complicated by its molecular characteristics, dysregulation mechanisms, and multiple cellular processes that are associated with KPNA2. This evidence concerns the gene KPNA2 and hepatocellular carcinoma.